AWS Life Sciences Symposium 2026 Event Brief
The 2026 Annual AWS Life Sciences Symposium brought together more than two thousand leaders across biopharma, technology, and research to examine how artificial intelligence is reshaping the industry.
Before the symposium, I had the privilege to sit down with the AWS Life Sciences leadership team for a deep dive on their roadmap for leveraging AWS technologies can revolutionize this industry.
Image Source: Axendia, Inc.
The event highlighted a sector moving beyond pilots and proofs of concept toward enterprise scale adoption of Future Ready Technologies. While the Symposium focused heavily on research, clinical, commercial innovation as well as medtech, it also underscored the opportunity to elevate Manufacturing and Supply Chain teams, the makers and builders who turn breakthrough science into real world therapies.
A central theme emerged across the sessions. The organizations realizing meaningful business impact from AI are those that treat it as an enterprise capability rather than a technology experiment. Dan Sheeran, Vice President and General Manager for Healthcare and Life Sciences at AWS, emphasized that point clearly.
“The organizations that are driving real business impact from AI have a mentality that AI is everyone’s responsibility. – Dan Sheeran, Vice President and General Manager Healthcare and Life Sciences, AWS
This shift in mindset is becoming a defining characteristic of companies that are successfully scaling AI across research, development, clinical, commercial, and enterprise operations.
This Event Brief provides Axendia’s analysis of the Symposium, the market forces shaping the industry, and the implications of AWS’s newest offering, Amazon Bio Discovery.
AI at a Scale: Moving Beyond Pilots
The Symposium underscored a widening gap between organizations that continue to run isolated pilots and those that have embraced AI as a strategic enterprise capability. Sheeran noted that many companies still experience “stalling that happens with pilots” because they treat AI as the responsibility of IT or innovation teams. These teams often lack access to production data, enterprise permissions, and compliance frameworks, which leads to shortcuts that break when pilots are pushed into production.
In contrast, companies like Eli Lilly and Genentech have adopted a fundamentally different approach. They build for production from the start and empower teams across the enterprise to become builders. Sheeran explained that once organizations move from team level experimentation to enterprise level adoption, “it is a super linear advance in your acceleration.”
This aligns with Axendia’s long-standing observation that Future Ready Technologies require both modernization and organizational change. Companies that treat AI as a strategic capability rather than a series of disconnected experiments are beginning to see meaningful returns.
Lilly’s Cortex Platform: AI as a Scientific Method
One of the most compelling perspectives came from Diogo Rau, Executive Vice President and Chief Information and Digital Officer at Eli Lilly. Rau framed AI not as a technology revolution but as an extension of the scientific method.
“Deploying AI across enterprises is the scientific method all over again. Observe, question, hypothesize, experiment, test, test, test, and then start it all over.” – Diogo Rau, Executive VP and Chief Information and Digital Officer at Eli Lilly
Lilly’s Cortex platform embodies this philosophy. Cortex provides a unified environment for both pro code and no code users, enabling developers and non-technical teams to access more than fifty large language models with consistent governance, security, and observability. Rau explained that Cortex eliminates the need for “six-week architecture reviews” because applications built on the platform automatically inherit enterprise guardrails.
The results are significant. Lilly now processes nearly one million prompts per month and fifteen billion tokens per month through Cortex. Rau shared that “literally just about every person in our company that is not working on a manufacturing line is using Cortex in some form.”
This level of adoption reflects a broader industry trend. Life sciences organizations are shifting from siloed digital initiatives to unified platforms that support enterprise scale AI and Future Ready Technologies.
Agentic AI in the Lab
The Symposium highlighted the growing role of agentic AI in laboratory environments. Lilly has implemented closed loop systems where AI agents observe, reason, plan, and act across digital and physical workflows. Rau described how this has transformed discovery operations. “What used to take us sixty chemists, and sixty thousand square feet of wet lab space now fits into just one hundred square feet.”
AWS reinforced this trend with the launch of Amazon Bio Discovery, a new AI powered application designed to unify and accelerate lab-in-the-loop drug discovery. The offering provides access to a catalog of biological foundation models, an AI agent that guides experiment design, and integrated lab partners for physical testing. Memorial Sloan Kettering Cancer Center shared how they use Amazon Bio Discovery to reduce antibody design cycles from months to weeks.
Be Your Own Orchestrator
Sheeran emphasized AWS’ position on the role of partner-built agents in enterprise AI strategies “partner agents have value, but only within narrow, system bound workflows. Some tasks remain fully contained within a vendor’s environment. In those cases, partner agents can be appropriate.”
However, most life sciences workflows require data and actions across multiple systems. “Vendor agents cannot see or act beyond their own walls,” Sheeran warned, “relying on partner agents creates fragmentation. Multiple agent frameworks, memory systems, identity models, observability stacks, and compliance surfaces lead to operational chaos.”
His guidance was direct. “Be your own orchestrator.” Enterprises must decide which partner agents to allow, what they can access, and which tasks must remain internal. He also made clear that partner agents cannot serve as an enterprise platform. “If you have multiple platforms, you have no platform.”
Axendia’s perspective is that implementing Future Ready Technologies requires unified governance, consistent guardrails, and enterprise-wide orchestration.
The Data Challenge: Context and Semantic Understanding
A recurring theme across the Symposium was the importance of data readiness for AI. AI agents require context, not just data. Sheeran explained that agents lack the institutional knowledge that humans take for granted. He shared an example where an AI system misclassified an orphan drug because it applied the United States threshold to a country where the criteria were different.
To address this, AWS introduced the concept of a semantic hub. This approach federates ontologies, taxonomies, business glossaries, and metadata across the enterprise, enabling agents to disambiguate terms, interpret relationships, and navigate data sources correctly.
This aligns with Axendia’s research on the need for semantic interoperability in regulated environments.
Enterprise Platforms and Agent Deployment
Another major focus of the Symposium was the challenge of building and deploying AI agents at scale. Sheeran noted that eighteen months ago, deploying a single agent into production could take “weeks to months.” Today, AWS demonstrated the ability to build and deploy an agent connected to the Open Targets API in five minutes.
This acceleration is driven by platforms like Amazon Bedrock AgentCore, which provides enterprise grade capabilities for identity, security, memory management, observability, and policy enforcement.
In Brief
The AWS Life Sciences Symposium 2026 showcased organizations that are no longer experimenting with AI but operationalizing it across the enterprise. AWS’s launch of Amazon Bio Discovery shows the company’s intent to be a central player in AI driven discovery, while customer developed platforms like platforms like Cortex demonstrate the importance of unified infrastructure for scale, governance, and compliance.
Lifecycle success will depend on connected data foundations, context aware intelligence, and harmonized experiences that reduce friction across discovery, development, clinical, manufacturing, and commercial operations
Organizations that modernize their data foundations and embrace intelligence driven operations will be positioned to convert complexity into clarity and disruption into advantage.
We will continue to provide updates on AWS as they become available.
To discuss how this initiative impacts your organization, click on this link to schedule an Analyst Inquiry on this topic.
The opinions and analysis expressed in this post reflect the judgment of Axendia at the time of publication and are subject to change without notice. Information contained in this post is current as of publication date. Information cited is not warranted by Axendia but has been obtained through a valid research methodology. This post is not intended to endorse any company or product and should not be attributed as such.